KIR3DL2 (Lacutamab Biosimilar) Recombinant Monoclonal Antibody

1. We show that KIR3DL2 expression is the most sensitive diagnostic criterion of Sezary syndrome when compared with all other available biological criteria. KIR3DL2 therefore represents a valuable tool for routine use as a clinical parameter at diagnosis, for prognosis and during patient follow-up PMID: 28119365
2. results identified significant KIR3DL2 expression in all cutaneous T-cell lymphomas subtypes PMID: 29089310
3. Overexpression of a single MHCI molecule, HLA-F, protects human MNs from ALS astrocyte-mediated toxicity, whereas knockdown of its receptor, the killer cell immunoglobulin-like receptor KIR3DL2, on human astrocytes results in enhanced motor neurons death PMID: 26928464
4. KIR-3DL2 binding to HLA-B27 licenses Th17 cell differentiation in spondyloarthritis. PMID: 26841353
5. In early axial spondyloarthritis and ankylosing spondylitis Dutch patients, no copy number changes were found for KIR3DL2. PMID: 25940819
6. we show that the allele KIR3DL2*001 and the single nucleotide polymorphism 1190T (rs3745902) are associated with differential susceptibility to pemphigus PMID: 25867094
7. CD158k expression was identified on cutaneous CD4+ T cells in healthy individuals and also mycosis fungoides patients. PMID: 25044837
8. These findings provide novel insights about the molecular basis of KIR3DL2 binding to B27 PMID: 25582852
9. these data provide evidence for a possible role of KIR3DL2 in the maintenance of a high circulating malignant-cell burden by preventing activation-induced cell death. PMID: 25414436
10. Our results indicate that KIR3DL2 can directly promote Sezary syndrome malignant cell death through the use of CpG ODN. PMID: 25007046
11. our results show that a multistep gating of CD158k+ cells is reliable to assess tumor burden in case of Sezary syndrome. PMID: 25158034
12. our results offer preclinical proof of concept for the clinical development of IPH4102, a humanized monoclonal antibody that targets the immune receptor KIR3DL2,to treat patients with nced cutaneous T-cell lymphoma PMID: 25361998
13. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. PMID: 23440420
14. PLS3, Twist, KIR3DL2 and NKp46 gene expression can model efficient molecular Sezary syndrome diagnosis. PMID: 23429988
15. most frequently expressed KIR receptor in transformed mycosis fungoides PMID: 22621189
16. results suggest that carriers of A allele in exon 3 of killer cell immunoglobulin-like receptor 3DL2(KIR3DL2) have a decreased susceptibility to preeclampsia PMID: 21406041
17. Enhanced proliferation, survival, and interleukin (IL)-17 production of KIR3DL2+ CD4 T cells stimulated with antigen-presenting cells expressing HLA-B27 homodimers suggest new therapeutic strategies in ankylosing spondylitis. PMID: 21248258
18. Data show direct binding of KIR3DL2 to ODNs and we show that the D0 domain is involved primarily in this interaction. PMID: 20147700
19. The A52G polymorphism in exon 3 and the frequencies of C32T in exon 9 of KIR3DL2 gene polymorphism are associated with the pathogenesis of pre-eclampsia. PMID: 19953898
20. All genotypes seen included genes for KIR3DL2. PMID: 12559621
21. IR3DL2/p140 engagement does not result into inhibitory (nor activatory) effects on tumor-specific cytotoxic T lymphocytes. PMID: 14562047
22. A high level of KIR3DL2 allelic polymorphism has been identified. PMID: 15304002
23. Receptor is a marker for the diagnosis of Sezary syndrome. PMID: 16962036
24. Five new alleles are reported, and four previously known ones are confirmed. PMID: 17661911
25. observation that CD4 positive, CD7 negative T-cells are mostly CD158k negative suggests that CD158k may be able to help identify and enumerate neoplastic T-cells in Sezary syndrome PMID: 18061949
26. Functional analysis of KIR3DL2-single positive natural killer (NK) cells reveals a subset that is hyporesponsive in individuals harboring cognate ligands HLA-A3/A11. PMID: 18941190
27. Anti-p140 autoantibodies represent a major autoantibody subset in juvenile dermatomyositis. PMID: 19479859
28. Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. PMID: 19165527

Show More

Hide All

HGNC: 6339

OMIM: 604947

KEGG: hsa:3812

STRING: 9606.ENSP00000325525

UniGene: Hs.645228